Visual field constriction and electrophysiological changes associated with vigabatrin

Documenta Ophthalmologica

Volumn 104, Issue 2, 2002, Pages 151-170

  Besch, Dorothea ^a   Kurtenbach, Anne ^a   Apfelstedt Sylla, Eckart ^a   Sadowski, Bettina ^a   Dennig, Dieter ^b   Asenbauer, Christiane ^c   Zrenner, Eberhart ^a   Schiefer, Ulrich ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b University of Tübingen ^*  (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

ERG; Oscillatory potentials; Vigabatrin; Visual field defect

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; VIGABATRIN;

4 AMINOBUTYRIC ACID RELEASE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLOR VISION TEST; COMPLEX PARTIAL SEIZURE; DARK ADAPTATION; ELECTRORETINOGRAPHY; EPILEPSY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MONOTHERAPY; MORPHOLOGY; NEUROTRANSMISSION; OSCILLATORY POTENTIAL; PATIENT REFERRAL; PERIMETRY; RETINA; RETINA CELL; SENSORY SYSTEM ELECTROPHYSIOLOGY; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION; WAVEFORM;

ADULT; AGED; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; ELECTROOCULOGRAPHY; ELECTRORETINOGRAPHY; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETINA; VIGABATRIN; VISUAL FIELDS;

EID: 0036219215     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014644307518     Document Type: Article

References (52)

1. Severe persistent visual field constriction associated with vigabatrin
2. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist
3. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing
4. Chronic refractory epilepsy may have role in causing these unusual lesions
5. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent
6. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin
7. Severe persistent visual field constriction associated with vigabatrin. Benefit: Risk ratio must be calculated for individual patients
8. Study is needed of visual field defects associated with any long term antiepileptic drug
9. Severe visual field constriction and side effects of GABA-mimetic antiepileptic agents
10. Symptomatic and asymptomatic visual field loss in patients taking vigabatrin
11. Visual dysfunction in patients receiving vigabatrin - Clinical and electrophysiologic findings
12. Visual field constriction in children treated with vigabatrin
13. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
14. Visual field defects associated with vigabatrin therapy
15. Characteristics of a unique visual field defect attributed to vigabatrin
16. What is specific about vigabatrin-induced visual field defects?
17. Manufacturers have started several studies
18. Is visual impairment related to vigabatrin reversible?
19. Reversibility of vigabatrin-induced visual-field defect
20. A study of the effects of vigabatrin on the central nervous system and retina of sprague dawley and lister-hooded rats
21. The neuropathology of vigabatrin
22. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor
23. A double-blind placebo controlled study of vigabatrin 32 g/day in patients with uncontrolled complex partial seizures
24. MRI findings in epileptic patients on vigabatrin for more than five years
25. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: Results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group
26. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin
27. Vigabatrin associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings
28. Outer retinal dysfunction in patients treated with vigabatrin
29. Effects of anticonvulsant drugs on retinal function. Psychophysical and electrophysiological findings on patients with epilepsy
30. Disorders of color reception and increased glare sensitivity in phenytoin and carbamazepine therapy: Ocular side effects of anticonvulsants
31. Application of video display units for campimetric purposes - Luminance characteristics and calibration procedures
32. Autokinetische Perimetrie bei Patienten mit Retinitis pigmentosa
33. Autokinetische Perimetrie/Kampimetrie - Prinzip und Einsatzbeispiele
34. Standard for clinical electroretinography
35. Standard for clinical electroretinography (1999 update)
36. Standard for clinical electro-oculography
37. The field topography of ERG components in man. I. The photopic luminance response
38. A topographic study of oscillatory potentials in man
39. Multifocal oscillatory potentials in Type 1 diabetics without retinopathy
40. Visual field defects: Pattern and epidemiology
41. Visual field defects and inner retinal dysfunction associated with vigabatrin
42. Vigabatrin induced optic neuropathy
43. Garbapentin and vigabatrin enhance promoted GABA release in rat hippocampus in vivo
44. Concentration-related pharmacodynamic study of vigabatrin and tiagabine in rat brain and eye
45. Visual field restriction with new anti-epileptic medication
46. Absence of concentric visual field defects in patients with initial tiagabine monotherapy
47. Electroretinographic changes are not associated with loss of function in pediatric epileptic patients following treatment with vigabatrin
48. Visual electrophysiological effect of a GABA transaminase blocker
49. The electroretinogram: Its components and their origin
50. Rod and cone system contributions to oscillatory potentials: An explanation for the conditioning flash
51. Immunocytochemical evidence that vigabatrin in rats cause GABA accumulation in glial cells of the retina
52. GABA transamination regulates neuronal glutamate content in the retina